Type of Cases |
Intensive Phase |
Continuation Phase |
New Case |
[2 –months] HRZE |
[4-months] HRE |
Previously Treated Case |
[2-months] HRZES + [1-month] HREZ |
[5-month] HRE |
Weight
Category in Kg |
Intensive
Phase: HRZE 75/150/400/275 mg |
Continuation
Phase: HRE75/150/275 mg |
Injection-
Streptomycin |
25—39 |
2 tablets |
2 |
.5gm |
40—54 |
3 tablets |
3 |
.75 gm |
55—69 |
4 tablets |
4 |
1gm |
>70 kg |
5 tablets |
5 |
1gm |
Age
Group (Years) |
Total
Patients |
Percentage
(%) |
10-19 |
09 |
15.2% |
20-39 |
40 |
67.8% |
40-60 |
07 |
11.9% |
>60 |
03 |
5.1% |
Sex |
No.
Of Patients |
Percentage
(%) |
Male |
28 |
47.4% |
Female |
31 |
52.4% |
System
Involved |
Type
of EPTB |
No.
of Cases |
Percentage |
Abdomen |
1) Acute |
24 |
40.67% |
2) Chronic |
07 |
11.86% |
|
Musculoskeletal |
Pott’s spine & Psoas Abscess |
08 |
13.55% |
Breast |
Lump, Sinus& Ulcer |
08 |
13.55% |
Lymph-nodes |
Cervical axillary |
05 |
8.47% |
Pleural tuberculosis |
EffusionEmpyema |
05 |
8.47% |
Male genital |
Penile |
01 |
1.69% |
Female genital |
Endometrial and Tubo-Ovarian |
01 |
1.69% |
Investigations |
No.
Of cases |
Percentage
(%) |
X-ray Chest |
59 |
100 |
X-ray Abdomen |
32 |
54.2 |
Ultrasonography |
53 |
89.8 |
CECT Abdomen/Chest |
09 |
15.3 |
FNAC |
20 |
33.9 |
PPD |
19 |
32.2 |
Histopathology |
33 |
55.9 |
Disease |
No.
Of Cases |
Type
of Surgery |
Intestinal Obstruction |
13 |
Exploratory Laparotomy |
Perforation Peritonitis |
06 |
Exploratory Laparotomy |
Pyoperitoneum |
02 |
Exploratory Laparotomy |
Omental T.B. |
02 |
Exploratory Laparotomy |
Ileal Stricture and mesentriclymph
nodes |
01 |
Exploratory Laparotomy |
Psoas Abscess |
08 |
Incision& Drainage Open/USG Guided |
Penile T.B. |
01 |
Circumcision |
Endometrial T.B. |
01 |
Diagnostic Dilatation & Curettage |
Empyema Thoracis |
01 |
Intercostal Chest Drainage |
Breast |
04 |
Incision & Drainage /Edge Biopsy |
Total |
39 |
|
Confirmed
Cases |
42 |
71.2% |
Clinical
Cases |
17 |
28.8% |
ATT
Completed |
50 |
84.7% |
ATT
Continued |
6 |
10.1% |
ATT
Defaulter |
2 |
3.4% |
Mortality |
1 |
1.7% |